221 related articles for article (PubMed ID: 30299387)
1. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
Dabrosin N; Sloth Juul K; Bæhr Georgsen J; Andrup S; Schmidt H; Steiniche T; Heide Øllegaard T; Bønnelykke Behrndtz L
Melanoma Res; 2019 Feb; 29(1):30-37. PubMed ID: 30299387
[TBL] [Abstract][Full Text] [Related]
2. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.
Jensen TO; Schmidt H; Møller HJ; Donskov F; Høyer M; Sjoegren P; Christensen IJ; Steiniche T
Cancer; 2012 May; 118(9):2476-85. PubMed ID: 21953023
[TBL] [Abstract][Full Text] [Related]
4. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
5. BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.
Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
JAMA Dermatol; 2015 Apr; 151(4):410-6. PubMed ID: 25588152
[TBL] [Abstract][Full Text] [Related]
6. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha.
Tas F; Erturk K
Cancer Chemother Pharmacol; 2019 Sep; 84(3):521-526. PubMed ID: 30997532
[TBL] [Abstract][Full Text] [Related]
9. The role of BRAF mutations in primary melanoma growth rate and survival.
Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
[TBL] [Abstract][Full Text] [Related]
10. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
11. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
12. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
de Moll EH; Fu Y; Qian Y; Perkins SH; Wieder S; Gnjatic S; Remark R; Bernardo SG; Moskalenko M; Yao J; Ferringer T; Chang R; Chipuk J; Horst BA; Birge MB; Phelps RG; Saenger YM
Cancer Immunol Immunother; 2015 Sep; 64(9):1193-203. PubMed ID: 26076664
[TBL] [Abstract][Full Text] [Related]
13. BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?
Mitchell B; Leone DA; Feller JK; Yang S; Mahalingam M
Hum Pathol; 2016 Jun; 52():19-27. PubMed ID: 26980024
[TBL] [Abstract][Full Text] [Related]
14. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
[TBL] [Abstract][Full Text] [Related]
16. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
17. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
18. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
[TBL] [Abstract][Full Text] [Related]
19. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.
Pinheiro C; Miranda-Gonçalves V; Longatto-Filho A; Vicente AL; Berardinelli GN; Scapulatempo-Neto C; Costa RF; Viana CR; Reis RM; Baltazar F; Vazquez VL
Cell Cycle; 2016 Jun; 15(11):1462-70. PubMed ID: 27105345
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1069-1077. PubMed ID: 28721890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
